

# Characterization of $\gamma\delta$ T cells in patients with non-small cell lung cancer

YI BAO<sup>1,2</sup>, LI GUO<sup>1</sup> and JUANFEN MO<sup>1</sup>

<sup>1</sup>Key Laboratory; <sup>2</sup>Department of Oncology,  
The Second Affiliated Hospital of Jiaying College, Jiaying, Zhejiang 314000, P.R. China

Received June 1, 2016; Accepted March 17, 2017

DOI: 10.3892/ol.2017.6191

**Abstract.** Systemic immune defects that are associated with disease progression exist in a variety of malignancies.  $\gamma\delta$  T cells are innate-like lymphocytes that do not require self-major histocompatibility complex-restricted priming. *Ex vivo*-expanded circulating  $\gamma\delta$  T cells exhibit promising antitumor activity and are a potential candidate for the treatment of various malignancies, including non-small cell lung cancer (NSCLC). In the present study, flow cytometry was used as a method to study the phenotypes and characteristics of  $\gamma\delta$  T cells. A lower frequency of circulating  $\gamma\delta$  T cells was observed in NSCLC patients than in healthy controls. In advanced NSCLC patients,  $\gamma\delta$  T cells were also detected in the pleural effusion, but the frequency of  $\gamma\delta$  T cells here was significantly lower than in the peripheral blood. V $\delta$ 1<sup>+</sup> and V $\delta$ 1<sup>+</sup>V $\delta$ 2<sup>-</sup> T cells represented the most enriched subsets in the pleural effusion. Moreover, the present study demonstrated that V $\delta$ 1<sup>+</sup> T cells are a type of  $\gamma\delta$  T cells characterized by a cluster of differentiation (CD)3<sup>dim</sup> T-cell receptor (TCR) $\gamma\delta$ <sup>bright</sup> phenotype, whereas V $\delta$ 2<sup>+</sup> T cells represent a CD3<sup>bright</sup>TCR $\gamma\delta$ <sup>dim</sup> phenotype, according to the fluorescence intensity of CD3 and  $\gamma\delta$ TCR using flow cytometry. Finally, the present study reported a decrease in the expression of CD27 and CD28 molecules on the surface of circulating  $\gamma\delta$  T cells in NSCLC. The present data suggest the existence of a dysregulated repertoire of  $\gamma\delta$  T cells in NSCLC, which exhibit impaired activation and a reformed cytokine-releasing profile. Although the *ex vivo* expansion of  $\gamma\delta$  T cells may be a prospective therapeutic strategy in NSCLC patients, it remains necessary to clarify which subsets (V $\delta$ 1 or V $\delta$ 2) should be expanded and the sources from which  $\gamma\delta$  T cells should be generated.

## Introduction

Unlike  $\alpha\beta$ T cells,  $\gamma\delta$  T cells represent a minor subset of T cells that does not require self-major histocompatibility complex (MHC)-restricted priming (1).  $\gamma\delta$  T cells are believed to serve as a bridge, connecting the innate and adaptive immune responses (1). Following infection by microbial pathogens,  $\gamma\delta$  T cells appear to be the first T cells to migrate to the lung (2). Previous studies have identified that  $\gamma\delta$  T cells can mediate antitumor activity (3).

In humans,  $\gamma\delta$  T cells are primarily identified by the V(D)J recombination of the  $\gamma$  and  $\delta$  chain genes, particularly their V $\delta$  chain usage (4). V $\delta$ 2 cells (mainly V $\gamma$ 9/V $\delta$ 2 cells) are the predominant  $\gamma\delta$  T-cell subset (50-75%) in the peripheral blood (PB) of healthy individuals (5). Uniquely, this subset of  $\gamma\delta$  T cells responds to phosphoantigens via polymorphic  $\gamma\delta$  T-cell antigen receptors (TCR) and undergoes rapid activation (6,7). Owing to the relative abundance in the PB and ease of expansion, V $\gamma$ 9/V $\delta$ 2 T-cell-based adoptive immunotherapy has been intensively investigated as the treatment for a variety of malignancies (8-10). V $\delta$ 1 T cells represent <30% of  $\gamma\delta$  T cells in the PB, but have been identified as an enriched subset in the thymus and in epithelial tissues, including the dermis, gut epithelium and spleen (11). Unlike V $\delta$ 2 cells, V $\delta$ 1 cells do not respond to phosphoantigens, but are able to recognize the MHC class I chain-related molecules A and B (12). A recent study suggested that V $\delta$ 1<sup>+</sup> T cells derived from the PB of normal donors are able to undergo *ex vivo* expansion by administration of phytohemagglutinin (PHA) and interleukin-7 (IL-7) (13); moreover, V $\delta$ 1 T cells exhibit more favorable antitumor activity than V $\delta$ 2 T cells in colon cancer (13). *Ex vivo*-expanded circulating  $\gamma\delta$  T cells represent a promising prospect in antitumor activities and are a potential candidate treatment for various malignancies, including non-small cell lung cancer (NSCLC). A phase I clinical study is currently being conducted using adoptive  $\gamma\delta$  T cell therapy in patients with advanced or recurrent NSCLC (14). However, the characterization of  $\gamma\delta$  T cells remains poorly understood in advanced NSCLC.

In the present study, the absolute count of lymphocytes and monocytes, and the subtypes and characteristics of  $\gamma\delta$  T cells in the PB and pleural effusion of advanced NSCLC patients were analyzed in order to investigate which subsets (V $\delta$ 1 or V $\delta$ 2) should be expanded *ex vivo* and used as the source from

---

*Correspondence to:* Dr Yi Bao, Key Laboratory, The Second Affiliated Hospital of Jiaying College, 1518 Huanchen North Road, Jiaying, Zhejiang 314000, P.R. China  
E-mail: ybao2011@gmail.com

**Key words:** non-small cell lung cancer,  $\gamma\delta$  T cells, peripheral blood, pleural effusion

which these  $\gamma\delta$  T cells should be generated for adoptive  $\gamma\delta$  T cell therapy.

## Materials and methods

**Subject recruitment and sample preparation.** The complete blood cell count of 102 patients with stage I-IV NSCLC using seventh edition of the TNM classification for lung cancer (15) (51 male, 51 female;  $64.45 \pm 1.55$  years of age; range, 48-86 years) who were admitted to the Department of Oncology, The Second Affiliated Hospital of Jiaying College (Jiaying, China) between January 2011 and December 2015, was retrospectively analyzed. Blood cell count data was also obtained from 114 cases of aged-matched healthy controls. Of the NSCLC patients and controls, 35 patients (stage III and IV) and 25 age-matched healthy individuals underwent  $\gamma\delta$  T-cell analysis in this study. Of these 35 patients, 10 were diagnosed as having stage IV NSCLC with malignant pleural effusion. Analysis of the characteristics of the  $\gamma\delta$  T cells in the pleural effusion of these 10 patients, together with another 2 elderly NSCLC patients ( $>75$  years of age) was conducted. The studies were approved by the Ethics Committee of The Second Affiliated Hospital of Jiaying College and written informed consent was obtained from each individual that provided a specimen. Study subjects did not have infectious diseases and had not undergone chemotherapy or radiotherapy in the previous week; however, certain patients and healthy donors did have chronic conditions, including hypertension, high cholesterol and diabetes.

**Isolation of mononuclear cells from pleural effusion.** Following collection of a 50-ml specimen of pleural effusion from 12 patients, mononuclear cells were isolated by centrifugation at  $1,000 \times g$  over a Ficoll-Paque (Beijing Solarbio Science & Technology Co., Ltd., Beijing, China) density gradient.

**Blood cell count.** A BC-5200 Hematology Analyzer (Beckman Coulter, Inc., Brea, CA, USA) was used to examine the absolute number of lymphocytes and monocytes in the present study.

**Flow cytometry staining.** To determine the identity of the biomarkers on the surface of  $\gamma\delta$  T cells, multicolored immunofluorescence staining was conducted using freshly collected blood samples and mononuclear cells isolated from the pleural effusion of the subjects. The antibodies were conjugated to fluorescent markers as follows: CD3-PE-Cy5.5 (cat. no. 340949), TCR  $\gamma\delta$ -APC (cat. no. 555718), TCR $\gamma\delta$ -FITC (cat. no. 559878), V $\delta$ 2-PE (cat. no. 3345652), CD27-PE (cat. no. 555441) and CD28-APC (cat. no. 559770). These antibodies, as well as isotype-matched control antibodies, were purchased from BD Pharmingen (dilution, ready to use; BD Biosciences, San Jose, CA, USA). V $\delta$ 1-FITC antibodies (cat. no. TCR2730) were purchased from Thermo Fisher Scientific, Inc., (Waltham, MA, USA). For extracellular staining, 50  $\mu$ l of each blood sample, and the mononuclear cells isolated from the pleural effusion which were in 1X PBS with 1% bovine serum albumin, were incubated with different combinations of fluorochrome-coupled antibodies (10  $\mu$ l of each antibody). After a 20-min incubation at room

Table I. Clinicopathological features of lung cancer patients in the present study (n=102).

Category	Value
Gender, n (%)	
Male	51 (50.0)
Female	51 (50.0)
Mean age $\pm$ SEM, years	$64.45 \pm 1.55$
Histology, n	
Adenocarcinoma	69
Squamous cell carcinoma	16
NSCLC (not specified)	17
TNM stage, n	
I-II	9
III	12
IV	81

SEM, standard error of the mean; NSCLC, non-small cell lung cancer; TNM, Tumor-Node-Metastasis classification system.

temperature, cells were washed twice with 1X PBS and flow cytometry was performed using a BD FACSCanto II flow cytometer (BD Biosciences). Data were collected and analyzed with DIVA software (version 6.1.3; BD Biosciences, San Jose, CA, USA).

**Statistical analysis.** Data are presented as the mean  $\pm$  standard error of the mean. Comparisons between groups were made using an unpaired Student's t-test. P-values  $<0.05$  were considered to indicate statistical significance. GraphPad Prism version 5 (GraphPad Software, Inc., La Jolla, CA, USA) was used for all statistical calculation and figure generation.

## Results

**Absolute number of lymphocytes and monocytes in the PB of NSCLC patients.** The complete blood cell counts of 102 patients (51 male, 51 female;  $64.45 \pm 1.55$  years) with stage I-IV NSCLC were retrospectively analyzed. The clinicopathological features of patients are provided in Table I. The blood cell count data were obtained from 114 cases of aged-matched healthy controls (51 male, 63 female; mean age,  $63.40 \pm 1.1$  years). The absolute number of lymphocytes and monocytes was assessed using an automatic hematology analyzer. The absolute value of lymphocytes (normal range,  $1.10$ - $3.20 \times 10^9/l$ ) in the PB was  $1.285 \times 10^9 \pm 0.049 \times 10^9/l$  in the NSCLC group, significantly lower than that of the healthy controls, where it was  $2.065 \times 10^9 \pm 0.051 \times 10^9/l$  ( $P < 0.001$ ) (Fig. 1A); however, the absolute value of monocytes (normal range is  $0.10$ - $0.60 \times 10^9/l$ ) was  $0.484 \times 10^9 \pm 0.022 \times 10^9/l$  in the NSCLC group, significantly higher than that in the healthy controls, where it was  $0.363 \pm 0.011$  ( $P < 0.001$ ) (Fig. 1B).

**Frequency of CD3 $^+$  $\gamma\delta^+$ T cells and V $\delta$ 1V $\delta$ 2 subtypes in circulation of NSCLC patients.** Flow cytometry was performed to determine the proportion of CD3 $^+$  $\gamma\delta^+$ T cells in the PB of




Figure 1. Retrospective analysis of the complete blood cell count in NSCLC patients. (A) A decrease was observed in the absolute number of lymphocytes in NSCLC patients ( $1.285 \times 10^9 \pm 0.049 \times 10^9/l$ ) compared with healthy controls ( $2.065 \times 10^9 \pm 0.051 \times 10^9/l$ ) ( $P < 0.001$ ). (B) An increase in the absolute number of monocytes was observed in NSCLC patients ( $0.484 \times 10^9 \pm 0.022 \times 10^9/l$ ) compared with healthy controls ( $0.363 \pm 0.011$ ) ( $P < 0.001$ ). \*\*\* $P < 0.001$ . NSCLC, non-small cell lung cancer; FSC, forward scatter; SSC, side scatter; TCR, T-cell receptor.

NSCLC patients. A total of 35 (stage III-IV) NSCLC patients (23 male, 12 female; mean age,  $65.7 \pm 1.3$  years) were examined in this study (2 NSCLC patients with pleural effusion were excluded owing to their old age,  $>75$  years old). The clinicopathological features of the patients are provided in Table II. In order to make a comparison, the frequency of  $\gamma\delta$  T cells were examined in 25 cases of age-matched healthy controls (17 male, 8 female; mean age,  $63.6 \pm 4.2$  years). Among these subjects, 20 patients with NSCLC and 11 healthy donors were further analyzed for the percentage of  $V\delta 1$  and  $V\delta 2$  T cells, two major subsets of  $\gamma\delta$  T cells, and the expression of the co-stimulatory markers CD27 and CD28. To assess the frequency of  $\gamma\delta$  T cells present in the sample, lymphocytes were first gated on the basis of a forward scatter/side scatter (FSC/SSC) profile, followed by  $\gamma\delta$  T-cell analysis in a gated population with  $CD3^+$  staining (Fig. 2A). A pan-TCR $\gamma\delta$  antibody was used to identify  $\gamma\delta$  T cells, and  $V\delta 1/V\delta 2$  antibodies were further used to determine  $V\delta 1$  and  $V\delta 2$  subsets (Fig. 2A). Fig. 2B shows that in NSCLC patients, the mean frequency of  $CD3^+\gamma\delta^+$  T cells was  $4.16 \pm 0.44\%$  ( $n=35$ ), whereas the value in healthy individuals was  $6.40 \pm 0.77\%$  ( $n=25$ ); the two groups have a statistically significant difference ( $P < 0.05$ ). In parallel with a previous report (16),  $V\delta 2$  T cells represented a major subset, and the  $V\delta 2/V\delta 1$  ratio was  $>1$  in the PB of all normal donors (100.0%) (11/11); however, in NSCLC patients, the  $V\delta 2^+$  T cells only represented a major subtype in 35.0% (7/20) of the population of  $\gamma\delta$  T cells;  $V\delta 1^+$  cells were counted as the priority  $\gamma\delta$  T cells in 35.0% (7/20) of patients, and in the rest of patients,  $V\delta 1-V\delta 2^-$  cells represented the main subset (6/20).

*Frequency of  $CD3^+\gamma\delta^+$  T cells and  $V\delta 1/V\delta 2$  subtypes in the PB and in the pleural effusion of advanced NSCLC patients.* To compare the difference between  $\gamma\delta$  T cells and  $V\delta 1/V\delta 2$  subtypes in the PB and pleural effusion in stage IV NSCLC patients, 12 patients (6 male, 6 female; mean age,  $70.2 \pm 9.2$  years) were recruited. The clinicopathological features of the patients are provided in Table III. The paired blood and pleural effusion samples were collected at the same time. The mean frequency of  $CD3^+\gamma\delta^+$  T cells was higher in the PB of the two groups ( $5.32 \pm 1.08\%$ ) than that in the pleural effusion of the two groups ( $2.47 \pm 0.69\%$ ), with a statistically significant difference ( $P < 0.05$ ) (Fig. 3A).

In the 12 NSCLC patients recruited for the current experiment, the  $V\delta 2^+\gamma\delta$  T cell was the predominant subtype in the PB in 5 patients (41.7%), whereas  $V\delta 1$  or  $V\delta 1-V\delta 2^-$  was the major  $CD3^+\gamma\delta^+$  T cell subtype in the remaining 7 patients (58.3%). In the pleural effusion,  $V\delta 1$  or  $V\delta 1-V\delta 2^-$  was the predominant subtype of  $CD3^+\gamma\delta$  T cells in all 12 patients (100.0%). In comparison to the frequency of  $V\delta 1^+$  and  $V\delta 2^+$  T cells between the PB and the pleural effusion, data from the present study showed that the percentage of  $V\delta 2$  T cells was significantly lower in the pleural effusion, with  $36.01 \pm 8.25\%$  of cells found to be T cells in the PB vs.  $8.16 \pm 2.38\%$  in the pleural effusion ( $P < 0.01$ ) (Fig. 3B). However, the percentage of  $V\delta 1$  T cells in the pleural effusion was significantly higher, with  $44.54 \pm 8.49\%$  of cells in the blood found to be T cells vs.  $64.78 \pm 5.50\%$  in the pleural effusion ( $P < 0.05$ ) (Fig. 3C).

*$V\delta 1$  and  $V\delta 2$  have different mean fluorescence intensity (MFI) for CD3 and TCR  $\gamma\delta$ .* Next, the expression of CD3 and TCR $\gamma\delta$  on the surface of the  $V\delta 1$  and  $V\delta 2$  T-cell population was analyzed. During the study of circulating  $V\delta 1$  and  $V\delta 2$  cells in the 20 NSCLC patients and 11 healthy donors, further analysis was performed, investigating the MFI of CD3 in  $V\delta 2$  and  $V\delta 1$   $\gamma\delta$  T cells. This analysis found that the MFI of CD3 was significantly higher in  $V\delta 2$  cells than in  $V\delta 1$  cells in NSCLC patients and healthy individuals; a CD3 MFI of  $4,776 \pm 691.2$  in  $V\delta 2^+$  cells vs.  $2,612 \pm 319.4$  in  $V\delta 1^+$  cells ( $n=20$ ;  $P < 0.01$ ) was observed in NSCLC patients (Fig. 4A), and a CD3 MFI  $9,689 \pm 1,270$  in  $V\delta 2^+$  cells vs.  $3,454 \pm 592.6$  in  $V\delta 1^+$  cells in healthy controls ( $n=11$ ;  $P < 0.001$ ) (Fig. 4B). The MFI of TCR $\gamma\delta$  was significantly lower in  $V\delta 2^+$  cells than in  $V\delta 1^+$  cells in NSCLC ( $858 \pm 62.49$  vs.  $2,614 \pm 313.10$ , respectively;  $n=20$ ;  $P < 0.001$ ) (Fig. 4C), and in healthy controls ( $1,351 \pm 182.8$  vs.  $3,724 \pm 725.20$ , respectively;  $n=11$ ;  $P < 0.01$ ) (Fig. 4D). Therefore,  $V\delta 2$  cells should be considered to be a population of  $CD3^{\text{bright}}TCR\gamma\delta^{\text{dim}}$  T cells, and by contrast,  $V\delta 1$  cells should be considered to be a population of  $CD3^{\text{dim}}TCR\gamma\delta^{\text{bright}}$  T cells.

*Expression of co-stimulatory markers CD27 and CD28 is decreased on the surface of  $CD3^+\gamma\delta^+$  T cells in patients with advanced NSCLC.* The TNF receptor family member CD27 is widely expressed on natural killer cells, and on  $CD4^+$  and

Table II. Clinicopathological features of stage III and IV lung cancer patients.

Category	Value
Gender, n (%)	
Male	23 (65.7)
Female	12 (34.3)
Mean age $\pm$ SEM, years	65.7 $\pm$ 1.3
Histology	
Adenocarcinoma	19
Squamous cell carcinoma	9
NSCLC (not specified)	7
TNM stage, n	
III	9
IV	26

NSCLC, non-small cell lung cancer; TNM, Tumor-Node-Metastasis classification system; SEM, standard error of the mean.

Table III. Clinicopathological features of advanced lung cancer patients with pleural effusion.

Category	Value
Gender, n (%)	
Male	6 (50.0)
Female	6 (50.0)
Mean age $\pm$ SEM, years	70.2 $\pm$ 9.2
Histology, n	
Adenocarcinoma	7
Squamous cell carcinoma	2
NSCLC (not specified)	3

SEM, standard error of the mean; NSCLC, non-small cell lung cancer.

CD8<sup>+</sup> T lymphocytes, as well as on  $\gamma\delta$  T cells (17). CD27 and its ligand, CD70, are involved in a signaling pathway that promotes the survival of primed T cells (18). CD28 is a well-documented co-receptor of  $\alpha\beta$ T cells, and activation of the CD3/CD28 pathway will enhance the proliferation of  $\alpha\beta$ T cells (19). Therefore, the expression of CD27 and CD28 on the surface of  $\gamma\delta$  T cells was investigated in the PB of the same 20 NSCLC patients and 11 healthy donors. The gating strategy is shown in Fig. 5A. In brief, lymphocytes were first gated based on their FSC/SSC profile, followed by analysis of CD27/CD28 expression in a gated population of CD3<sup>+</sup> $\gamma\delta$ <sup>+</sup> cells (Fig. 5A). There was a significantly increased frequency of CD27-CD28-CD3<sup>+</sup> $\gamma\delta$ <sup>+</sup> T cells in the PB of NSCLC patients (40.2 $\pm$ 5.7%) compared with the PB of the healthy control group (11.9 $\pm$ 4.8%) ( $P < 0.01$ ) (Fig. 5B). An increased population of CD27-CD28-CD3<sup>+</sup> $\gamma\delta$ <sup>+</sup>T cells was also observed in the pleural effusion of NSCLC patients compared with that in the PB, but the difference was not statistically significant (data not shown).





Figure 2. Identification and characterization of a population of  $\gamma\delta$  T cells and  $V\delta 1^+V\delta 2^+$  subtypes in the lymphocytes. (A) Cells were gated as lymphocytes and then CD3<sup>+</sup>T cells. Subsequently, the presence of TCR $\gamma\delta^+$  T cells was assessed in CD3<sup>+</sup> T cells. In the population of CD3<sup>+</sup>TCR $\gamma\delta^+$  T cells,  $V\delta 1^+V\delta 2^+$  and  $V\delta 1^+V\delta 2^-$  were further gated and analyzed. (B) The percentage of CD3<sup>+</sup> $\gamma\delta$  T cells in NSCLC patients and healthy controls (4.16 $\pm$ 0.44 vs. 6.40 $\pm$ 0.77%, respectively;  $P < 0.05$ ). \* $P < 0.05$ . NSCLC, non-small cell lung cancer; FSC, forward scatter; SSC, side scatter; TCR, T-cell receptor; CD, cluster of differentiation.

## Discussion

In the present study, decreased numbers of lymphocytes and increased numbers of monocytes were observed in the PB of NSCLC patients. This observation supports previous reports concerning the systemic immune defects that exist in malignancies, which include low numbers of circulating T cells and low chemokine levels, and enhance the number of anti-tumor T cells that are likely to partially reverse immunosuppressive activities (20). A low lymphocyte-to-monocyte ratio (LMR) has been shown to be an independent unfavorable prognostic factor for predicting survival in SCLC patients (21). A lower LMR most likely have decreased cytotoxic T lymphocytes and higher tumor-associated macrophages (22). A previous study reported that the monocyte count in the peripheral blood was higher in the patients with cervical and endometrial cancer compared with a control group of healthy blood donors (23). An elevated number of peripheral monocytes has also been associated with a poor prognosis for patients with lung adenocarcinoma (24).






Figure 3. Comparison of  $\gamma\delta$  T cells and V $\delta$ 1V $\delta$ 2 subsets between the PB and pleural effusion in paired samples derived from advanced non-small cell lung cancer patients. (A) There was a decreased percentage of CD3<sup>+</sup> $\gamma\delta$ <sup>+</sup>T cells in the pleural effusion compared with the PB ( $2.47\pm 0.69$  vs.  $5.32\pm 1.08\%$ , respectively;  $P<0.05$ ). (B) A higher percentage of V $\delta$ 2 cells were present in the population of CD3<sup>+</sup> $\gamma\delta$ <sup>+</sup>T cells in the PB compared with the pleural effusion ( $36.01\pm 8.25$  vs.  $8.16\pm 2.38\%$ , respectively;  $P<0.01$ ). (C) There was a lower percentage of V $\delta$ 1 T cells in the PB than in the pleural effusion ( $44.54\pm 8.49$  vs.  $64.78\pm 5.50\%$ , respectively;  $P<0.05$ ). \* $P<0.05$ . \*\* $P<0.01$ . PB, peripheral blood; CD, cluster of differentiation.




Figure 4. Expression of CD3 and TCR $\gamma\delta$  molecules on the surface of V $\delta$ 1 and V $\delta$ 2 T cell subsets in the circulation of NSCLC patients and healthy individuals. (A) The MFI of CD3 was decreased in V $\delta$ 1 cells compared with that in V $\delta$ 2 cells in the group of NSCLC patients ( $2,612\pm 319.4$  vs.  $4,776\pm 691.2$  AU, respectively;  $P<0.01$ ). (B) The MFI of CD3 in V $\delta$ 1<sup>+</sup> cells was decreased compared with that in V $\delta$ 2 cells in the group of normal individuals ( $3,454\pm 592.6$  vs.  $9,689\pm 1,270$  AU, respectively;  $P<0.001$ ). (C) The MFI of TCR $\gamma\delta$  in V $\delta$ 1 cells was increased compared with V $\delta$ 2 in the group of NSCLC patients ( $2,614\pm 313.10$  vs.  $858\pm 62.49$  AU, respectively;  $P<0.001$ ). (D) The MFI of TCR $\gamma\delta$  in V $\delta$ 1 T cells was increased compared with that in V $\delta$ 2 cells in the group of normal individuals ( $3,724\pm 725.20$  vs.  $1,351\pm 182.8$ , respectively;  $P<0.01$ ). \*\* $P<0.01$ . \*\*\* $P<0.001$ . NSCLC, non-small cell lung cancer; MFI, mean fluorescence intensity; TCR, T-cell receptor; CD, cluster of differentiation.

The number of  $\gamma\delta$  T cells is lower in elderly individuals than in the young population (25). The present study also observed a decrease in the frequency of  $\gamma\delta$  T cells in the PB of NSCLC patients. Circulating V $\delta$ 2  $\gamma\delta$  T cells appeared to lose their predominance in NSCLC patients compared with healthy individuals; V $\delta$ 1, and to a lesser extent V $\delta$ 1-V $\delta$ 2 $\gamma\delta$ , T cells became a major subset and the ratio of V $\delta$ 2:V $\delta$ 1 T cells inverted in one-third of all studied patients; a similar observation has been reported in a study of  $\gamma\delta$  T cells in gastric

cancer (26). On the basis of previous studies, V $\delta$ 1 T cells are less susceptible to activation-induced cell death and exhaustion than V $\delta$ 2 T cells (27,28). V $\delta$ 1 T cells are also preferentially persistent *in vivo*; this could be the reason why V $\delta$ 1 T cells are predominant in the PB of patients with lung cancer.

In the present study,  $\gamma\delta$  T cells were also detected in the pleural effusion of patients with advanced NSCLC, in whom the frequency of V $\delta$ 2<sup>+</sup> T cells was even lower than in the PB, and V $\delta$ 1 or V $\delta$ 1-V $\delta$ 2 $\gamma\delta$  T cells acted as the predominant




Figure 5. Identification of the co-stimulatory markers CD27 and CD28 on the surface of CD3<sup>+</sup> $\gamma\delta$ <sup>+</sup>T cells in patients with advanced NSCLC. (A) Cells were gated as lymphocytes and then CD3<sup>+</sup> $\gamma\delta$ <sup>+</sup>T cells. Subsequently, the presence of TCR $\gamma\delta$ <sup>+</sup> cells was assessed for in CD3<sup>+</sup>T cells. In the population of CD3<sup>+</sup> $\gamma\delta$ <sup>+</sup>T cells, the expression of CD27 and CD28 was further gated and analyzed. (B) There was a significantly increased frequency of CD27<sup>+</sup>CD28<sup>+</sup>CD3<sup>+</sup> $\gamma\delta$ <sup>+</sup>T cells in the peripheral blood of NSCLC patients compared with healthy controls (40.2±5.7 vs. 11.9±4.8%, respectively; P<0.01). \*\*P<0.01. NSCLC, non-small cell lung cancer; TCR, T-cell receptor; CD, cluster of differentiation.

subsets in all subjects studied. To the best of our knowledge, no previous study has reported on the characteristics of  $\gamma\delta$  T cells and their subsets in the pleural effusion of NSCLC. Tumor-infiltrating leukocytes (TILs) represent a wide range of variety of immune cells that have been found in invading solid tumors, and the extent of infiltration of  $\gamma\delta$  T cells is reported to enable a variety of prognostic predictions, for example; in the earlier stages of melanoma there are higher percentages of intra-tumoral  $\gamma\delta$  T cells, particularly V2 $\gamma\delta$  T cells, compared with advanced stage melanoma, which serves as a biomarker of good prognoses; in contrast, a higher level of intra-tumoral V1  $\gamma\delta$  T cells has been reported as a poor prognostic factor in breast cancer (29,30). In a study of  $\gamma\delta$  T cells in the TILs of melanoma,  $\gamma\delta$  T cells were detected in 76% of tumor specimens using immunohistochemistry. V $\delta$ 1 was the major subset presenting in 52% of samples (31,32). In a study of  $\gamma\delta$  T cells in human colon cancer, it was found that the majority (80%) of IL-17<sup>+</sup> $\gamma\delta$  T cells expressed V $\delta$ 1 ( $\gamma\delta$ 17), and those cells that infiltrated  $\gamma\delta$ 17 T cells in the tumor were associated with advanced tumor grades and progression. As

a result, these T cells may serve as prognostic markers in human colon cancer (33). However, Peng *et al* (34) reported that the V $\delta$ 1 subtype was observed to be the dominant subtype among tumor infiltrating lymphocytes in a group of breast cancer patients, and that it appeared to exhibit a broad range of immune suppression activities, via suppressing the production of IL-2 by CD4<sup>+</sup> and CD8<sup>+</sup> T cells, and the maturation of dendritic cells. The present study indicates that  $\gamma\delta$  T cells derived from the pleural effusion could be a source of adoptive  $\gamma\delta$  T cell immunotherapy in lung cancer. Unlike for V $\delta$ 2 T cells, which respond to phosphoantigens, there is no protocol concerning the expansion of V $\delta$ 1<sup>+</sup> populations *ex vivo*, although a recent study indicated that PHA and IL-7 may be candidates to facilitate expansion of the V $\delta$ 1 subtype in circulating  $\gamma\delta$  T cells (13). However, the present authors have been unable to obtain a satisfactory result on the *ex vivo* expansion of V $\delta$ 1 or V $\delta$ 2 cells, either using PHA and IL-7 stimulation or zoledronic acid when using the  $\gamma\delta$  T cells isolated from pleural effusion in advanced NSCLC (Bao *et al*, unpublished data). This is likely to be due to the low frequency of  $\gamma\delta$  T cells in the pleural effusion, and the fact that the majority  $\gamma\delta$  T cells are V $\delta$ 1 T cells. Moreover, it remains unclear whether there are similar antitumor effects of V $\delta$ 1 T cells derived from PB or from pleural effusion in lung cancer patients.

In the present study, V $\delta$ 2 T cells appeared to be a population of  $\gamma\delta$  T cells with a CD3<sup>bright</sup>TCR $\gamma\delta$ <sup>dim</sup> phenotype; by contrast, V $\delta$ 1 T cells were characterized by a CD3<sup>dim</sup>TCR $\gamma\delta$ <sup>bright</sup> phenotype. A previous study suggested that TCR $\gamma\delta$ -deficient mice display reduced tumor growth compared with wild-type animals (35). The different levels of CD3 and TCR $\gamma\delta$  expression may indicate that in these two subsets, a variety of co-stimulatory signaling pathways could be involved in the regulation of activation and proliferation.

The present study found a decrease in the expression of CD27 and CD28 molecules on the surface of circulating  $\gamma\delta$  T cells in NSCLC patients. A previous study showed a majority of V $\delta$ 2 cells in PB are CD27<sup>+</sup> $\gamma\delta$  T cells (36). Another prior study reported evidence supporting an absolute requirement of CD27 for the expansion of  $\gamma\delta$  T cells by employing a CD27-deficient mice model. CD27 and its ligand CD70 are involved in a signaling pathway that is required to promote the survival of primed T cells (17,37). In the thymus of mice, CD27 is likely to regulate  $\gamma\delta$  T cell differentiation, and CD27<sup>+</sup> $\gamma\delta$  T cells produce interferon (IFN)- $\gamma$ , whereas CD27<sup>-</sup> $\gamma\delta$  T cells produce IL-17 (38). In  $\alpha\beta$  T cells, 'signal 1', which refers to the mature T cells recognizing and binding to a major histocompatibility complex (MHC) molecule carrying a peptide antigen through their antigen-specific receptors (TCR), together with a co-stimulatory pathway, CD28/B7, provides a 'second signal' that is required for the activation and proliferation of T cells (39); this CD28/B7 pathway involves the interaction of co-stimulatory molecule CD28 with its ligands B7-1 (CD80) and B7-2 (CD86) on the antigen presenting cells, and is critical for T-cell activation, proliferation, and survival (40); however, the requirement of the additional CD28/B7 signal for the activation of  $\gamma\delta$  T cells remains controversial (41). In studying lymphocytes isolated from the lymph node, it was apparent that CD28 is expressed on the surface of  $\gamma\delta$  T cells and has the capability to promote the activation of  $\gamma\delta$  T cells, as well as their proliferation and survival, mainly by

stimulating  $\gamma\delta$  T cells to produce and secrete IL-2 (42,43). Data obtained from a study of CD28-deficient mice suggested that the population of IFN- $\gamma$  and IL-17 $^+$  $\gamma\delta$  T cells failed to expand during infection (43,44), indicating that CD28 co-stimulation is also necessary for  $\gamma\delta$  T cell expansion. Downregulation of CD27 and CD28 molecules in circulating  $\gamma\delta$  T cells in NSCLC patients suggests an impaired capacity to activate and proliferate  $\gamma\delta$  T cells in those patients, and indicates that they have a different cytokine profile to healthy individuals (42).

The present data suggested the presence of a dysregulated repertoire of  $\gamma\delta$  T cells, including impaired activation and a reformed cytokine releasing profile of  $\gamma\delta$  T cells in NSCLC. Although the *ex vivo* expansion of  $\gamma\delta$  T cells may be a prospective therapeutic strategy in NSCLC patients, it remains necessary to clarify which subsets (V $\delta$ 1 or V $\delta$ 2) should be expanded and the sources from which these  $\gamma\delta$  T cells should be generated.

### Acknowledgements

The authors thank Dr Bing Chen (University of Liverpool, Liverpool, UK) for providing revisions to the manuscript. This study was supported by grants from the Chinese National Science Fund for Young Scholars (Beijing, China; no. 81101707), the Natural Science Foundation of Zhejiang Province (Hangzhou, China; no. LY16H070007), the Health Bureau of Zhejiang Province (Hangzhou, China; no. 2016KYB292) and the Zhejiang Traditional Chinese Medicine Foundation Project (Hangzhou, China; no. 2014ZB119).

### References

- Urban EM, Chapoval AI and Pauza CD: Repertoire development and the control of cytotoxic/effector function in human gammadelta T cells. *Clin Dev Immunol* 2010: 732893, 2010.
- Dieli F, Ivanyi J, Marsh P, Williams A, Naylor I, Sireci G, Caccamo N, Di Sano C and Salerno A: Characterization of lung gamma delta T cells following intranasal infection with *Mycobacterium bovis* bacillus Calmette-Guérin. *J Immunol* 170: 463-469, 2003.
- Paul S and Lal G: Regulatory and effector functions of gamma-delta ( $\gamma\delta$ ) T cells and their therapeutic potential in adoptive cellular therapy for cancer. *Int J Cancer* 139: 976-985, 2016.
- Legut M, Cole DK and Sewell AK: The promise of  $\gamma\delta$  T cells and the  $\gamma\delta$  T cell receptor for cancer immunotherapy. *Cell Mol Immunol* 12: 656-668, 2015.
- Porcelli S, Brenner MB and Band H: Biology of the human gamma delta T-cell receptor. *Immunol Rev* 120: 137-183, 1991.
- Constant P, Davodeau F, Peyrat MA, Poquet Y, Puzo G, Bonneville M and Fournié JJ: Stimulation of human gamma delta T cells by nonpeptidic mycobacterial ligands. *Science* 264: 267-270, 1994.
- Tanaka Y, Morita CT, Tanaka Y, Nieves E, Brenner MB and Bloom BR: Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. *Nature* 375: 155-158, 1995.
- Meraviglia S, Eberl M, Vermijlen D, Todaro M, Buccheri S, Cicero G, La Mendola C, Guggino G, D'Asaro M, Orlando V, *et al*: In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. *Clin Exp Immunol* 161: 290-297, 2010.
- Abe Y, Muto M, Nieda M, Nakagawa Y, Nicol A, Kaneko T, Goto S, Yokokawa K and Suzuki K: Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma. *Exp Hematol* 37: 956-968, 2009.
- Kobayashi H, Tanaka Y, Yagi J, Minato N and Tanabe K: Phase I/II study of adoptive transfer of  $\gamma\delta$  T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma. *Cancer Immunol Immunother* 60: 1075-1084, 2011.
- Bonneville M, O'Brien RL and Born WK: Gammadelta T cell effector functions: A blend of innate programming and acquired plasticity. *Nat Rev Immunol* 10: 467-478, 2010.
- Wu J, Groh V and Spies T: T cell antigen receptor engagement and specificity in the recognition of stress-inducible MHC class I-related chains by human epithelial gamma delta T cells. *J Immunol* 169: 1236-1240, 2002.
- Wu D, Wu P, Wu X, Ye J, Wang Z, Zhao S, Ni C, Hu G, Xu J, Han Y, *et al*: Ex vivo expanded human circulating V $\delta$ 1  $\gamma\delta$ T cells exhibit favorable therapeutic potential for colon cancer. *Oncoimmunology* 4: e992749, 2015.
- Kakimi K, Matsushita H, Murakawa T and Nakajima J:  $\gamma\delta$  T cell therapy for the treatment of non-small cell lung cancer. *Transl Lung Cancer Res* 3: 23-33, 2014.
- Rusch VW, Asamura H, Watanabe H, Giroux DJ, Rami-Porta R and Goldstraw P; Members of IASLC: The IASLC lung cancer staging project: A proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. *J Thorac Oncol* 4: 568-577, 2009.
- Casorati G, De Libero G, Lanzavecchia A and Migone N: Molecular analysis of human gamma/delta+ clones from thymus and peripheral blood. *J Exp Med* 170: 1521-1535, 1989.
- Born WK and O'Brien RL:  $\gamma\delta$  T cells develop, respond and survive-with a little help from CD27. *Eur J Immunol* 41: 26-28, 2011.
- Borst J, Hendriks J and Xiao Y: CD27 and CD70 in T cell and B cell activation. *Curr Opin Immunol* 17: 275-281, 2005.
- Salomon B and Bluestone JA: Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. *Annu Rev Immunol* 19: 225-252, 2001.
- Frey AB and Monu N: Signaling defects in anti-tumor T cells. *Immunol Rev* 222: 192-205, 2008.
- Go SI, Kim RB, Song HN, Kang MH, Lee US, Choi HJ, Lee SJ, Cho YJ, Jeong YY, Kim HC, *et al*: Prognostic significance of the lymphocyte-to-monocyte ratio in patients with small cell lung cancer. *Med Oncol* 31: 323, 2014.
- Yang J, Liao D, Chen C, Liu Y, Chuang TH, Xiang R, Markowitz D, Reisfeld RA and Luo Y: Tumor-associated macrophages regulate murine breast cancer stem cells through a novel paracrine EGFR/Stat3/Sox-2 signaling pathway. *Stem cells* 31: 248-258, 2013.
- Jóźwik M, Okunbowa OE, Lipska A, Jóźwik M, Smoktunowicz M, Semczuk A and Jóźwik M: Surface antigen expression on peripheral blood monocytes in women with gynecologic malignancies. *BMC Cancer* 15: 129, 2015.
- Kumagai S, Marumo S, Shoji T, Sakuramoto M, Hirai T, Nishimura T, Arima N, Fukui M and Huang CL: Prognostic impact of preoperative monocyte counts in patients with resected lung adenocarcinoma. *Lung Cancer* 85: 457-464, 2014.
- Vasudev A, Ying CT, Ayyadhury S, Puan KJ, Andiappan AK, Nyunt MS, Shadan NB, Mustafa S, Low I, Rotzschke O, *et al*:  $\gamma\delta$  T cell subsets in human aging using the classical  $\alpha\beta$  T cell model. *J Leukoc Biol* 96: 647-655, 2014.
- Kuroda H, Saito H and Ikeguchi M: Decreased number and reduced NKG2D expression of V $\delta$ 1  $\gamma\delta$  T cells are involved in the impaired function of V $\delta$ 1  $\gamma\delta$  T cells in the tissue of gastric cancer. *Gastric Cancer* 15: 433-439, 2012.
- Siegers GM and Lamb LS Jr: Cytotoxic and regulatory properties of circulating V $\delta$ 1+  $\gamma\delta$  T cells: A new player on the cell therapy field? *Mol Ther* 22: 1416-1422, 2014.
- Godder KT, Henslee-Downey PJ, Mehta J, Park BS, Chiang KY, Abhyankar S and Lamb LS: Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation. *Bone Marrow Transplant* 39: 751-757, 2007.
- Dieli F, Stassi G, Todaro M, Meraviglia S, Caccamo N and Cordova A: Distribution, function and predictive value of tumor-infiltrating  $\gamma\delta$  T lymphocytes. *Oncoimmunology* 2: e23434, 2013.
- Ma C, Zhang Q, Ye J, Wang F, Zhang Y, Wevers E, Schwartz T, Hunborg P, Varvares MA, Hoft DF, *et al*: Tumor-infiltrating  $\gamma\delta$  T lymphocytes predict clinical outcome in human breast cancer. *J Immunol* 189: 5029-5036, 2012.
- Zocchi MR, Ferrarini M and Rugarli C: Selective lysis of the autologous tumor by delta TCS1+ gamma/delta+ tumor-infiltrating lymphocytes from human lung carcinomas. *Eur J Immunol* 20: 2685-2689, 1990.
- Zocchi MR, Ferrarini M, Migone N and Casorati G: T-cell receptor V delta gene usage by tumour reactive gamma delta T lymphocytes infiltrating human lung cancer. *Immunology* 81: 234-209, 1994.

33. Wu P, Wu D, Ni C, Ye J, Chen W, Hu G, Wang Z, Wang C, Zhang Z, Xia W, *et al*:  $\gamma\delta$ T17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer. *Immunity* 40: 785-800, 2014.
34. Peng G, Wang HY, Peng W, Kiniwa Y, Seo KH and Wang RF: Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. *Immunity* 27: 334-348, 2007.
35. Rei M, Gonçalves-Sousa N, Lanca T, Thompson RG, Mensurado S, Balkwill FR, Kulbe H, Pennington DJ and Silva-Santos B: Murine CD27(-) V $\gamma$ 6(+)  $\gamma\delta$  T cells producing IL-17A promote ovarian cancer growth via mobilization of protumor small peritoneal macrophages. *Proc Natl Acad Sci USA* 111: E3562-E3570, 2014.
36. Dieli F, Poccia F, Lipp M, Sireci G, Caccamo N, Di Sano C and Salerno A: Differentiation of effector/memory Vdelta2 T cells and migratory routes in lymph nodes or inflammatory sites. *J Exp Med* 198: 391-397, 2003.
37. DeBarros A, Chaves-Ferreira M, d'Orey F, Ribot JC and Silva-Santos B: CD70-CD27 interactions provide survival and proliferative signals that regulate T cell receptor-driven activation of human  $\gamma\delta$  peripheral blood lymphocytes. *Eur J Immunol* 41: 195-201, 2011.
38. Ribot JC, deBarros A, Pang DJ, Neves JF, Peperzak V, Roberts SJ, Girardi M, Borst J, Hayday AC, Pennington DJ and Silva-Santos B: CD27 is a thymic determinant of the balance between interferon-gamma- and interleukin 17-producing gammadelta T cell subsets. *Nat Immunol* 10: 427-436, 2009.
39. Smith-Garvin JE, Koretzky GA and Jordan MS: T cell activation. *Annu Rev Immunol* 27: 591-619, 2009.
40. Lenschow DJ, Walunas TL and Bluestone JA: CD28/B7 system of T cell costimulation. *Annu Rev Immunol* 14: 233-258, 1996.
41. Ribot JC, deBarros A and Silva-Santos B: Searching for 'signal 2': Costimulation requirements of  $\gamma\delta$  T cells. *Cell Mol Life Sci* 68: 2345-2355, 2011.
42. Ribot JC and Silva-Santos B: Differentiation and activation of  $\gamma\delta$  T Lymphocytes: Focus on CD27 and CD28 costimulatory receptors. *Adv Exp Med Biol* 785: 95-105, 2013.
43. Ribot JC, DeBarros A, Mancio-Silva L, Pamplona A and Silva-Santos B: B7-CD28 costimulatory signals control the survival and proliferation of murine and human  $\gamma\delta$  T cells via IL-2 production. *J Immunol* 189: 1202-1208, 2012.
44. Ribot JC, Chaves-Ferreira M, d'Orey F, Wencker M, Gonçalves-Sousa N, Gonçalves-Sousa N, Decalf J, Simas JP, Hayday AC and Silva-Santos B: Cutting edge: Adaptive versus innate receptor signals selectively control the pool sizes of murine IFN- $\gamma$ - or IL-17-producing  $\gamma\delta$  T cells upon infection. *J Immunol* 185: 6421-6425, 2010.